Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BioNTech Jumps as Shot for Teens Clears First UK Hurdle

Published 06/04/2021, 01:12 PM
Updated 06/04/2021, 01:14 PM
© Reuters

By Dhirendra Tripathi

Investing – BioNTech (NASDAQ:BNTX) shares were up more than 6% Friday after its proposal to be allowed to provide COVID-19 vaccines for 12- to 15-year-olds in the UK got past the country’s medicine regulator.

The proposal now needs the nod of the UK's Joint Committee on Vaccination and Immunization. It will go to the Health and Social Care department from there.

The company had last Friday it secured approval from the European Medicines Agency for use of its COVID-19 vaccine in children of the same age group.

Children aged 12-15 years are already receiving the shot in the U.S.

Pfizer and BioNTech have so far committed to delivering 2.4 billion doses of the vaccine through 2023 to various countries.

The vaccine is based on BioNTech's proprietary mRNA technology. The German company has a tie-up with Pfizer (NYSE:PFE) to make and market the vaccine in geographies mutually distributed between the two.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.